Using high-dose testosterone to treat advanced prostate cancer in men with specific genetic mutations
High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency
['FUNDING_OTHER'] · VA PUGET SOUND HEALTHCARE SYSTEM · NIH-10980514
This study is looking at how high doses of testosterone might help men with advanced prostate cancer who have specific gene mutations, and it involves giving monthly testosterone shots while still using other treatments to control hormone levels; the goal is to see if this approach can lower PSA levels and improve quality of life, all while keeping an eye on any side effects.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VA PUGET SOUND HEALTHCARE SYSTEM (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10980514 on ClinicalTrials.gov |
What this research studies
This research investigates the effects of high-dose testosterone on men suffering from metastatic castration-resistant prostate cancer who have mutations in the ATM or CDK12 genes. The approach involves administering intermittent high-dose testosterone through monthly intramuscular injections while continuing androgen deprivation therapy to manage testosterone levels. The study aims to determine the treatment's effectiveness by measuring changes in PSA levels and assessing quality of life through surveys. Patients will be monitored for any adverse effects throughout the treatment period.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have specific genetic mutations in ATM or CDK12.
Not a fit: Patients without these genetic mutations or those with other forms of prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that may improve survival and quality of life for men with advanced prostate cancer.
How similar studies have performed: Previous studies have shown promising results with high-dose testosterone in similar patient populations, suggesting potential for success in this approach.
Where this research is happening
SEATTLE, UNITED STATES
- VA PUGET SOUND HEALTHCARE SYSTEM — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MONTGOMERY, BRUCE — VA PUGET SOUND HEALTHCARE SYSTEM
- Study coordinator: MONTGOMERY, BRUCE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced prostate cancer, androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer